论文部分内容阅读
目的探讨急性髓系白血病缓解期化疗后应用G-CSF的必要性。方法采用自身前后对照,比较了24例急性髓系白血病患者两次化疗后用与不用G-CSF的感染率、感染时间和医疗费用情况。结果用与不用G-CSF感染率分别为79.2%和87.5%,差异无统计学意义(P>0.05);用G-CSF较未用感染时间要缩短(1.75±1.69)d(P<0.01);用G-CSF者的医疗费用要超过未用者(P<0.05)。结论急性髓系白血病患者缓解期常规方案化疗后使用G-CSF有利于缩短感染期,但从经济上考虑预防性使用G-CSF是非必需的。
Objective To investigate the necessity of using G-CSF after chemotherapy in remission of acute myeloid leukemia. Methods A total of 24 patients with acute myeloid leukemia were enrolled in this study. The infection rates, the time of infection and the medical costs of patients with and without G-CSF after chemotherapy were compared. Results The rates of infection with and without G-CSF were 79.2% and 87.5%, respectively, with no significant difference (P> 0.05) ; The medical expenses of those who used G-CSF surpassed the unused ones (P <0.05). CONCLUSIONS: Acute myeloid leukemia patients treated with G-CSF after conventional regimen during remission may be beneficial to shorten the infection period, but the preventive use of G-CSF is not economically necessary.